Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM sleep behavior disorder in patients with LBD. In addition, it focuses on developing RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-20-3318-9708
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees45
OptionableOptionable
Axovant Sciences (NASDAQ:AXON) Frequently Asked Questions
What is Axovant Sciences' stock symbol?
Axovant Sciences trades on the NASDAQ under the ticker symbol "AXON."
How were Axovant Sciences' earnings last quarter?
Axovant Sciences Ltd (NASDAQ:AXON) announced its earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.10. View Axovant Sciences' Earnings History.
When is Axovant Sciences' next earnings date?
What price target have analysts set for AXON?
5 equities research analysts have issued 1-year price targets for Axovant Sciences' stock. Their forecasts range from $3.00 to $7.00. On average, they expect Axovant Sciences' share price to reach $4.6667 in the next year. This suggests a possible upside of 362.0% from the stock's current price. View Analyst Price Targets for Axovant Sciences.
What is the consensus analysts' recommendation for Axovant Sciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axovant Sciences in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Axovant Sciences.
What are Wall Street analysts saying about Axovant Sciences stock?
Here are some recent quotes from research analysts about Axovant Sciences stock:
- 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (1/7/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to the achievement of target price. Our price target of $7/share is based on an equally-weighted composite of: (a) $6.27/share, as a 35x multiple of taxed and diluted $2.30 discounted back to FY18 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $7.26/share (discounted cash flow analysis using a 15% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/13/2018)
- 3. Chardan Capital analysts commented, "We now assign an incremental $2/share of value to AXON based on AXON capturing some of this value. We expect Oxford BioMedica striking new partnerships in the GT space will provide further upside to shares from here. We note that Axovant has strengthened its management with the addition of gene therapy experts to its leadership. Axovant announced the addition of Dr. Michael Hayden as Chairman of its SAB. Dr. Hayden “played a key role in the discovery and development of Glybera”. With this deal, Axovant announced its new CTO will be Dr. Fraser Wright, the co-founder and former CTO of Spark Therapeutics (Buy)." (6/6/2018)
Has Axovant Sciences been receiving favorable news coverage?
Press coverage about AXON stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Axovant Sciences earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.
Are investors shorting Axovant Sciences?
Axovant Sciences saw a increase in short interest in December. As of December 31st, there was short interest totalling 4,519,607 shares, an increase of 51.1% from the December 14th total of 2,991,736 shares. Based on an average daily trading volume, of 1,484,014 shares, the short-interest ratio is presently 3.0 days. Currently, 8.7% of the shares of the stock are short sold. View Axovant Sciences' Current Options Chain.
Who are some of Axovant Sciences' key competitors?
Some companies that are related to Axovant Sciences include BioSpecifics Technologies (BSTC), Theratechnologies (THERF), Prothena (PRTA), Innate Pharma (IPHYF), GlycoMimetics (GLYC), Eidos Therapeutics (EIDX), Corium International (CORI), ZEALAND PHARMA/S (ZEAL), Odonate Therapeutics (ODT), Akorn (AKRX), Forty Seven (FTSV), Arcus Biosciences (RCUS), Evolus (EOLS), Corbus Pharmaceuticals (CRBP) and Clementia Pharmaceuticals (CMTA).
Who are Axovant Sciences' key executives?
Axovant Sciences' management team includes the folowing people:
- Dr. Pavan Cheruvu M.D., CEO & Director (Age 36)
- Dr. Gregory M. Weinhoff, Principal Financial & Accounting Officer (Age 47)
- Mr. Mark Altmeyer, Pres & Chief Commercial Officer of Axovant Sciences GmbH (Age 57)
- Dr. David T. Hung, Scientific Advisor of Group (Age 60)
- Dr. Fraser Wright, Chief Technology Officer
When did Axovant Sciences IPO?
(AXON) raised $251 million in an initial public offering on Thursday, June 11th 2015. The company issued 17,900,000 shares at a price of $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.
How do I buy shares of Axovant Sciences?
Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Axovant Sciences' stock price today?
One share of AXON stock can currently be purchased for approximately $1.01.
How big of a company is Axovant Sciences?
Axovant Sciences has a market capitalization of $123.50 million. The biotechnology company earns $-221,570,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Axovant Sciences employs 45 workers across the globe.
What is Axovant Sciences' official website?
How can I contact Axovant Sciences?
Axovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at 44-20-3318-9708.
MarketBeat Community Rating for Axovant Sciences (NASDAQ AXON)
MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences and other stocks. Vote "Outperform" if you believe AXON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXON will underperform the S&P 500 over the long term. You may vote once every thirty days.
